Emerging chemotherapy drugs and targeted therapies have been widely applied in anticancer treatment and have given oncologists a promising future. Nevertheless, regeneration and recurrence are still huge obstacles on the way to cure cancer. Cancer stem cells (CSCs) are capable of self-renewal, tumor initiation, recurrence, metastasis, therapy resistance, and reside as a subset in many, if not all, cancers. Therefore, therapeutics specifically targeting and killing CSCs are being identified, and may be promising and effective strategies to eliminate cancer. MicroRNAs (miRNAs, miRs), small noncoding RNAs regulating gene expression in a post-transcriptional manner, are dysregulated in most malignancies and are identified as important regulators of CSCs. However, limited knowledge exists for biological and molecular mechanism by which miRNAs regulate CSCs. In this article, we review CSCs, miRNAs and the interactions between miRNA regulation and CSCs, with a specific focus on the molecular mechanisms and clinical applications. This review will help us to know in detail how CSCs are regulated by miRNAs networks and also help to develop more effective and secure miRNA-based clinical therapies.
INTRODUCTION
Malignancies have taken numerous lives and are depriving more humans of the right to live. It is estimated that about 12.7 million new cancer cases and 7.6 million cancer deaths occurred in 2008 worldwide, and, in developing countries, patients with malignancy tend to be diagnosed at later stages compared with developed countries, resulting in rare access to appropriate treatments. 1 Timely diagnosis and rational therapeutics will undoubtedly help to improve cancer morbidity and mortality.
Cancer stem cells (CSCs), which compose a small fraction of the tumor bulk, show high capacities for sphere-forming, self-renewal, migration, invasion and resistance to chemoradiotherapy, [2] [3] [4] contributing to initiating and propagating neoplastic growth. CSCs stay in a 'hibernation' state, a form of quiescence associated with slow cell-cycle kinetics. 5 Current anticancer therapies are less likely to result in long-term remissions as chemotherapy targets proliferative cells. The development of new therapies that specifically target and eliminate CSCs are imperative. MicroRNAs (MiRNAs, MiRs) govern diverse biological functions by inhibiting messenger RNAs (mRNAs). Compared with traditional chemoradiotherapy, certain miRNAs show greater potential for anticancer therapy by suppressing both cancer cells and CSCs through regulating cancer related genes, signaling and transcriptional factors. miRNAs may provide a precise predictor for evaluating prognosis and therapeutic outcome. In this review, we focus on CSCs and miRNAs regulation of CSCs, and the prospect of using miRNAs as targets both for diagnostics and treatments will also be provided.
MOLECULAR BIOLOGY AND FUNCTIONS OF MIRNAS
Recognition of miRNAs The group of tiny, single-strand, 18-26 nt long RNAs is attracting more and more attention. miRNAs regulate mRNAs at the posttranscriptional level, acting as tight regulators of developmental genes and are involved in various pathophysiological processes. The biogenesis of the cascade of miRNAs was shown Figure 1 . Target recognition by miRNA depends mainly on the 2-8 base seed sequence of their 5 0 ends as a determinant of specificity. 6 What is more, the interaction with the 3 0 UTR are often imperfectly complementary, meaning each miRNA could regulate the expression of many mRNAs, made translation cleavage or repression 7 ( Figure 2 ). At this time, over 20 000 miRNAs have been discovered and, through the post-transcriptional modulation of targeted mRNAs, they are playing crucial roles in multiple biological processes, such as differentiation, embryonic development, cell cycle, proliferation, survival, stress resistance, fat metabolism, immune defense, virus-related diseases and, most importantly, tumorigenesis. 8, 9 MiRNAs in tumorigenesis and progression The miRNAs targeting mRNAs were often discovered at translocation breakpoints, deletions and amplification sites, accounting for 50% of all fragile regions or cancer-associated sites, 10 while oncogenic miRNAs are located mainly in the amplified regions, and tumor suppressive miRNAs are located mainly in the deleted regions in human cancer. 11 Upregulation of oncogenic miRNAs in carcinoma may inhibit the tumor suppressors by amplifying the miRNA encoding locus. Downregulation of tumor suppressive miRNAs by deletion or methylation of the miRNA locus may result in oncogenes overexpression. 8 Located in chromosome 13 and amplified in human B cell lymphomas, lung cancer and human breast cancer, miR-17-92 function as an anti-apoptotic miRNA cluster by targeting intrinsic apoptotic protein Bim in B-cell lymphoma subtypes. 12, 13 Research focusing on miR-21 in cancer and its target genes revealed that miR-21 could target different genes in different tumor, including p53 and transforming growth factor-b (TGF-b) in glioblastoma, PTEN in hepatocellular carcinoma, nuclear phosphoprotein 32 family member A/alias pp32/LANP (ANP32A) in human prostate cancers, SMARCA4 (alias BRG1) in B-cell lymphoma and tropomyosin 1 (TPM1) in breast cancer MCF-7 cells. 12, 14, 15 Acting as tumor-suppressive miRNAs, miR-15a and the miR-16-1 cluster promote apoptotic response by targeting the antiapoptotic gene BCL-2. The loss of miR-29 cluster, located in 7q32, leads to acute myeloid leukemia by losing control of their target proteins like BCL-2, MCL1 and CDK6, facilitating cancer progression. 12, 16 Let-7 miRNAs are also widely accepted as tumor suppressors by influencing various targeted genes (Supplementary Table S1 ). miRNAs influence tumor biology by acting as signal modulators in which they proved to be important components of cancer relevant pathways, for example, through targeting CDK6, CARD10 and CDC27, which could promote cell-cycle progression, miR-15a/ miR-16-1 cluster could amplify the roles of miRNAs. 10 The substantial roles of miRNAs in regulating the malignant biological processes and the multiple interactions between miRNAs and mRNAs suggest that miRNAs regulation of tumor progression is complicated and may include epigenetic reprogramming and signaling pathways.
The effects of miRNAs on epigenetic reprogramming Cell differentiation was considered as irreversible in the past. However, reprogramming process governed and mediated by transcription factors (TFs), noncoding RNAs and epigenetic modifiers were continually discovered, which could override the cellular identity and induce reprogramming of cellular fates (Figure 3a ). Ectopic expression of TF was noticed for its roles of Figure 2 . Mechanisms of miRNA biological functions. Mature miRNA molecule, argonaute2 (AGO2) protein, and accessory proteins assemble the miRNA-induced silencing complex (RISC), where the miRNA strand locates within the 3 0 UTRs of targeted mRNA to regulate the stability and translation efficiency, through an antisense mechanism, resulting in their degradation or translational repression. Figure 1 . Biogenesis and generation of miRNAs. Most miRNAs are located within the introns of coding or non-coding genes; they are transcribed as primary transcripts (pri-miRNAs) and then cleaved by the Drosha ribonuclease to produce 65-70 long stem-loop precursors (pre-miRNAs) in the nucleus. These pre-miRNAs are exported to the cytoplasm via the shuttle protein exportin-5 and are processed by Dicer in the cytoplasm, generating mature miRNAs.
concerting cells states in many experiments, as were summarized by Alexander and co-workers 17 Diverse somatic starting cells originating from different species can be reprogrammed to pluripotency with variable but consistently low efficiency by regulating selected TFs, for example, ectopic expression of TFs Sox2, Oct4, STAT3, KLF4 and c-Myc in fibroblasts of adult and embryonic cells could convert these cells to induced pluripotent stem cells with pluripotency/stemness. 18, 19 miRNAs were correlated with epigenetic reprogramming by epithelial mesenchymal transition (EMT) more often. EMT is associated with the loss of intercellular junctions, epithelial polarity and the increase in cell motility, playing a fundamental role during the early steps of tumorigenesis, invasion and metastasis, which allows cancer cells to infiltrate adjacent stroma and metastasize to distant sites, playing crucial roles in reprogramming together with mesenchymal to epithelial transition 20 ( Figure 3a) . Zhang et al. found about 300 known human miRNA genes in breast cancer and showed that 72.8% of them are located in regions that exhibit DNA copy number abnormalities, and in another study, mir-320 is found to be located in regions with DNA copy number loss, with methyl CpG-binding protein 2 (MECP2) being the predicated target. 12 Our team found that miR-17/20 and let-7 were probably involved in TFs-related gene regulation by cyclin-D1/CDK and other reprogramming factors, which may also regulate a group of miRNAs in regulatory loops 21 ( Figure 3b ). The EMT process is regulated by different epigenetic and posttranscriptional mechanisms as well as signaling pathways and was preliminarily involved in the conversion of epithelial cells to mesenchymal cells. 22 Lots of chromatin changes were detected in EMT and, in addition, by showing oncogenic or tumor suppressive activity, let-7, miR-10, miR-34, miR-200, miR-205 and some other miRNAs could induce phenotypic changes (Figure 3c ). What's more, the TFs implicated in epigenetic reprogramming were often targeted genes of miRNAs and, reversely, these miRNAs could be regulated directly by TFs. For example, on the one hand, miR-200 family, miR-205 and miR-34 are regulated by p53 and TGF-b. 23 On the other hand, TGF-b could activate the TFs, which repress the expression of miR-200 family members 22 ( Figure 3c ). MiR-302 reprogrammed normal cells to pluripotent stem cells state through promotion Sox2, Oct4 and Nanog expression. 24 Irregular expressions of miRNAs in induced pluripotent stem cells, embryonic stem cells and CSCs strengthened their effects on maintaining or converting cellular identities by driving typespecific gene expression programs. These experimental manipulations of cell fates will have a far-reaching influence on both molecular mechanisms of cellular identities and eventual application to personalized regenerative and anticancer treatment.
miRNAs and therapy resistance Chemotherapy resistance (chemoresistance) and radiotherapy resistance (radioresistance) are always the toughest problem in anticancer treatment. Membrane transporters exclude anticancer drugs from the cytoplasm, inducing detoxification and insensitivity to drug-induced apoptosis, contributing to multidrug miRNAs and CSCs in cancer research X Sun et al resistance (MDR). The ATP-binding cassette (ABC) transporters (ABCG2/BCRP1, ABCB1/MDR1 and ABCA3), COX-2, Ras, Cyclin-D1, Bcl-2 and Survivin were proved to play critical roles in drug resistance. [25] [26] [27] The well-known cancer-related signal pathways, such as the epidermal growth factor receptor, extracellular signalregulated kinase, mitogen activated protein kinase and nuclear factor-kappa B also contributed. Besides genetic and epigenetic alterations, recent data revealed that chemoradiotherapy resistance could also be regulated by post-transcriptional regulators: miRNAs. Discoveries of miRNAs made anticancer therapy promising, for nearly all proteins and signal pathways referring to therapy resistance have been identified as target genes of miRNAs, which could adjust cellular response to anticancer therapy via affecting signaling pathways, apoptotic responses and DNA repair systems. [28] [29] [30] Liang and Xu et al. 31 found that lower expression of miR-297 in colorectal cancer was correlated with multidrug resistance in part by modulation of MDR-associated protein 2. MiR-212/328 were both identified to be inversely correlated with ABCG2 expression after long-term treatment with imatinib in CML cells by targeting the 3 0 UTR of ABCG2 mRNA. 32, 33 By exploring HCC patient samples, Borel et al. 34 demonstrated that ABCA1, ABCC1, ABCC5, ABCC10 and ABCE1 could be mediated by 13 miRNAs, meaning miRNAbased therapies may be an effective way to interfere ABC expression and overcome clinical MDR. Let-7 miRNAs affected acquired resistance of ovarian cells to taxol or vinblastine by targeting IMP-1, then restoring the sensitivity chemotherapy. 35 Besides, miRNAs were implicated in the regulation of drug metabolism by influencing key receptors or enzymes contributing to drug resistance, and these studies paved the way for therapeutic strategies targeting drug-resistant cancer cells. Radiotherapy is one of the most widely used anticancer treatments, ranking second only to surgery, improving overall survival for patients with early-stage and advanced malignancies. 36, 37 MiR-125b decreased intercellular adhesion molecule-2 expression, which could facilitate the apoptoticblocking survival through PI3K/AKT phosphorylation and caspase-3 activation, resulting in cancer cell radioresistance. 38, 39 CANCER STEM CELLS The theory of CSCs Tumors are known to be heterogeneous containing a dynamic mixture of phenotypically and functionally different cells, and this heterogeneity is attributed to the hierarchy that originates from a small population of cancer stem cells that are distinct from the bulk tumor and are blamed for capacity of tumorigenesis, therapy resistance and metastasis. 40, 41 Although possessing the ability to self-renew and to differentiate into other cell subpopulations, many differences existed among embryonic stem cells, adult stem cells, induced pluripotent stem cells and CSCs. [41] [42] [43] embryonic stem cells could divide and differentiate into different tissues and organs at specific periods. Adult stem cells rest on G0 phase with a quiescent state and only divide when injuries occur. Stem cells in adult tissues are in homeostasis, replenishing the tissues and organs in response to environmental cues or stimulations, which were constrained by diverse mechanisms. However, CSCs could proliferate and divide beyond controlling programs and are characterized by the ability to form tumors when transplanted into animal hosts. 44 The asymmetrical divisions of stem cells allow them to self-renew and generate progenitor cells, whereas the asymmetric division of CSCs will retain their identity, undergo cell division and maintain a niche where they were sustained. Asymmetric and symmetric divisions are referred to different outcomes of CSCs self-renewal. 45 We are exploring whether let-7 miRNA family members could induce asymmetric division of CSCs and inhibit CSCs malignant potential through influencing cyclin-D1 (cell cycle and DNA damage) and p53 (cell polarity of self-renewing divisions) expression by using PKH staining. 45 The origins of CSCs are still being disputed. One theory insists that CSCs come from normal stem cell with gene mutations and epigenetic reprogramming, as several CSCs were similar to corresponding normal stem cells in cell phenotypes, cellular function and property. The second theory supposed that differentiation of progenitor cells paused and stem-like characteristics were activated. Another theory believes that the CSCs arose from normal cells, which obtained malignant characteristics in development through reprogramming or EMT, and finally cancer cells acquired stem-like behaviors 41 ( Figure 3a) . CSCs theory considered themselves as one of the subclones exhibiting characteristics of heterogeneity within tumor bulk, showing high capacities for tumor initiation, self-renewal and multilineage differentiation that sharing characteristics with normal stem cells. 46, 47 They likely retain the features and mechanisms protecting normal stem cells from external damages and give rise to populations of identical and differentiated progenies after injuries. 4, 48 CSCs may reside in specific microenvironment or niches where they could maintain and differentiate. It is well established that normal stem cells of various tissues reside in a niche or microenvironment tightly influencing their fate and selfrenewal. 49 CSCs may resemble normal stem cells in regard to the influence of the tumor microenvironment on their behavior and characteristics. For example, through interacting with the ECM, integrin-a6 has been shown to be expressed on CD133 þ glioma CSCs, allowing enrichment for CSCs, and its targeting resulted in inhibited tumorigenicity, proliferation and self-renewal. 50 Isolation and identification of CSCs In comparison to the tumor bulk, CSCs developed distinct phenotypes due to a variety of stimulations, which helped us to isolate and identify these cells. By now, there had been several assays to separate CSCs from multiple solid tumors. CSCs could be distinguished by using serial sphere (colony) forming unit assays, label-retention assays, magnetic activated cell sorting and flow cytometric cell sorting. Different cell surface antigens and metabolic markers have been identified in various tumors as surface markers of CSCs, relying on which, magnetic activated cell sorting and flow cytometric cell sorting offered us sensitive and specific methods to isolate and purify subsets enriched of CSCs, as were shown in Supplementary Table S2 . Notably, these markers were likely tissues-and tumors-specific, useful to identify and isolate CSCs possessing the capacity of self-renewing, generating and differentiating into polytypic cancer cells in vitro and in vivo. In routine researches, another universal CSC marker defined by Hoechst dye efflux properties was called side population (SP) phenotype. SP assay is initially developed to enrich hematopoietic stem cells owing to their expression of high levels of drugdetoxifying ABC transporters proteins, such as ABCG2 and MDR1 that efficiently efflux the Hoechst dye 33342. 51 SP cells may be an enriched source of CSCs with more tumorigenic capacity, as well as a trigger for cancer cell proliferation and metastasis. 52 What is more, this phenotype was correlated with drug-resistance, which we will discuss later.
The properties of initiating tumors and driving neoplastic proliferation, creating endless copies through self-renewal and giving rise to numerous mature non-CSCs progenies through differentiation are necessary for identifying CSCs. 53 Based on these properties, methods to confirm identify of CSCs were demonstrated, for example, phenotype identification, sphere forming assays and xenotransplantation assays. Although the assays used to define CSCs in each type differed, common to stemness of cancer cells comes from the xenotransplantation/ serial transplantation into animal models. When transplanted into an orthotopic site of non-obese diabetic/severe combined miRNAs and CSCs in cancer research X Sun et al immune-deficient mouse, small amount of CSCs could regenerate the uniform tumors resembling the original one, and the CSCs should be isolated from the planted tumors and grafted into a second recipient animal. 41 CSCs population should reestablish the phenotypic heterogeneity and exhibit self-renewing capability on serial cell passaging without being lost.
Self-regulation pathways of CSCs
The signal pathways of Wnt, Notch, Hedgehog, fibroblast growth factor, TGF-b, SHH, EGF and BMP will allow stem cells to undergo uncontrolled proliferation and carcinogenesis through autocrine/ paracrine signaling pathways. These signaling networks are implicated in tissue homeostasis by regulating the endogenous reprogramming mechanisms, extracellular and intracellular matrix, cell membrane and nucleus. [54] [55] [56] Irregular changes of stem cell signaling network in normal stem cells may lead to the transformation to CSCs by EMT or genetic alterations, and regulate the self-renewal and survival of CSCs.
The Wnt pathway is closely related with oncogenic phenotypes and plays an important role in regulating cell development and stem cell function. Wnt signals may be transduced to the canonical pathway for cell fate determination, the noncanonical pathway for cell movement or the noncanonical Wnt/calcium pathway. 57 All these pathways are activated by Wnt ligand binding to Frizzled (Fzd) family receptors or low-density lipoprotein receptor (LRP5/6), which then activates disheveled (Dsh), finally inactivating GSK3b/ Axin/APC phosphorylation complex and stabilizing b-catenin. The accumulation of unphosphorylated b-catenin (free b-catenin) enters the nucleus, resulting in abnormal regulations by binding to T cell factor/lymphoid enhancer factor, and finally promoting oncogenes and carcinogenesis. In the absence of Wnt, the GSK3b/Axin/APC complex induces the phosphorylation and degradation of b-catenin. 58 Wnt is implicated in EMT by H3K79 histone methyltransferase methylate H3K79 on the promoters of Fzd receptors. 59 The inhibitors of Wnt signal pathway may provide effective agents to reduce the hostility of CSCs and may be a promising method to inhibit the uncontrolled cell renewal.
Notch signaling is a conserved pathway in multi-cellular organisms, which could regulate cells fate specification, differentiation, maintain tissue homeostasis and result in EMT during development and tumor regression through direct regulation of snail and slug as well as through crosstalk with TGF-b, fibroblast growth factor, platelet derived growth factor and crosstalk with fibroblast growth factor, TGF-b and platelet derived growth factor. 22 Notch receptors are single-pass transmembrane proteins composed of several functional proteins, which are processed in golgi through cleavage and glycosylation, producing a glycosylated Ca 2 þ stabilized heterodimer, and finally the receptor will be transported to the plasma membrane to enable ligands binding. Different epigenetic mechanisms in the Notch activator complex are required to activate Notch target genes, such as hairy/enhancer-of-splitrelated transcriptional repressor (Hey1) and Notch-1 receptor. 60 Loss of Hey1 impairs transformation or cardiac-associated EMT, leading to inhibition of tumorigenesis or congenital heart defects. The histone chaperone antisilencing factor 1 is linked to Notch signaling and required for acetylation of H3K5/6, levels of which are increased in multiple types of cancer and correlated with increased antisilencing factor 1 levels. 61 The hedgehog signaling proteins play crucial roles in development of diverse organisms, regulating morphogenesis of a variety of tissues and organs. Hedgehog signaling is involved in control of stem cell proliferation and development in adult tissues, and its aberrant regulation was proved to be related to multiple types of human malignancies.
Epigenetic reprogramming and EMT in CSCs
Widespread epigenetic reprogramming occurs during stem cell differentiation and malignant transformation, and EMT is one of the examples of cellular plasticity, which is crucial for cancer progression. EMT is characterized as a reversible procedure of cells plasticity, and neoplastic epithelial cells undergoing EMT might represent the fraction of CSCs occurring in many carcinomas. 62 Epigenetic reprogramming are potentially reversible modifications in DNA methylation and chromatin without any changes in DNA sequences. Epigenetic regulations like TFs and noncoding RNAs (alternative splicing, miRNAs and lncRNAs) contribute a lot during EMT and epigenetic reprogramming, inducing malignant process and transformation of CSCs (Figure 3a) . These chromatin modifiers and histone mark changes were mostly identified during drosophila development and some of the target genes regulated by the Notch/Wnt pathways can induce EMT, metastasis and tumor progression in mammalian cells. 22 Regulated heterochromatin were identified for EMT and then drive cancer cell migration and chemoresistance. 62 After undergoing EMT, cells and cancer cells acquired stemness and malignant-type traits. These processes could be general mechanism for inducing epigenetic plasticity and reprogramming and help to adjust existing strategies to treat cancer cells and CSCs. The interference towards reprogramming and EMT in CSCs generation and progression may be valuable for specific treatments targeting CSCs. 49 CSCs and chemoradiotherapy resistance CSCs had been blamed for their critical roles in therapy resistance since they were defined, resulting in enormous difficulties to cure cancer. As discussed above, CSCs in tumors are resting populations. Unfortunately, existing common chemoradiotherapy could only target and kill the rapidly proliferating cells; these CSCs will successfully escape from being eliminated. Li et al. 63 examined the proportion of CD44 þ /CD24 À /low breast cancer stem cells before and after treatments with docetaxel, doxorubicin, cyclophosphamide and trastuzumab chemotherapies, and finally the percentage of BCSCs increased after 12 weeks treatment. Similar research showed that radiation with doses between 2 Gy and 6 Gy induced enrichment of CSCs in MCF-7 breast cancer cells. 64 CSCs in mammary tumors were testified to be resistant to cisplatin and paclitaxel in vitro and in vivo; and mouse breast CSCs displayed less H2A phosphorylation to radiation, which is a hallmark of DNA double-strand breaks. [65] [66] [67] CD133 þ CSCs in glioblastoma showed distinct resistance to temozolomide, carboplatin, paclitaxel, etoposide and displayed resistance to radiation due to increased activation of the DNA damage checkpoint kinases CHK1, CHK2 and Wnt signaling, which made DNA repairing more efficient and undergoing less apoptosis, relative to CD133 À cells. 47, 64, 68 Glioblastoma is one of the most lethal malignancies of which radiotherapy seemed to be the only effective nonsurgical treatment, and the determinant CSCs of radiotherapy resistance of glioblastoma could definitely sensitize cancer cells to radiation. 47 Serial transplantation of colorectal cancer revealed that ALDH1 þ CSCs enriched after receiving chemotherapy and mediated the resistance to cyclophosphamide. 69 Later, Mihatsch et al. 70 demonstrated that ALDH1 activity is indicative of subpopulations of lung and breast cancer cells with increased radioresistance. The increased snail and slug in ovarian cancer cell progression lead to enhanced cell survival and acquisition of stemness by repressing p53-induced apoptosis, of the outcome of which is resistance to radiation and chemotherapy. 71 The isolation of CSCs relying on ABC transporters made these CSCs naturally resistant to most drugs, and high expression of ABCG2 were also demonstrated in purified fraction of SP cells. Besides, microenvironment factors and CSCs niches showed significant influence on stemness and therapy resistance, for hypoxia could protect some CSCs from being eliminated by radiation through hypoxia-inducible factors (HIFs). 64 The response miRNAs and CSCs in cancer research X Sun et al of cancer cells to radiation is determined by intrinsic cellular radiosensitivity, microenvironmental factors and the delivery methods, and it is likely that elimination of CSCs will significantly improve the radiation response of tumor. 36 Intrinsic and extrinsic determinants, such as enchased DNA repair capability, protection from oxidative DNA damage by enhanced ROS scavenging and activation of the cell survival pathways in CD44 þ /CD24 À /low human breast cancer and CD44 þ human gastric cancer may partly determine tumor recurrence after radiotherapy. 40, 72, 73 These studies provided clinical evidence of chemoradiotherapy resistant CSCs, while the mechanisms causing this resistance are still obscure. CSCs could accumulate mutations continually as an outcome of receiving long-term therapies; the daughter cancer cells consequently will inherit this property, becoming more and more resistant and tenacious.
Therapies aiming at CSCs Most therapies preferentially target rapid proliferative cancer cells, showing rare cytotoxic effects on non-dividing or slow-dividing cells. These quiet and steady CSCs are secure under multitherapies bombing; just endure unto staging a comeback. More specific drugs or agents targeting CSCs are crying needs (Figure 4a ). Some studies showed that by aiming at CSCs via molecular phenotypes, tumors could be nearly eliminated. Inhibition of several enzymes, proteins, kinases and signaling pathways can decrease cell proliferation, tumor burden, chemoradiotherapy resistance and recurrence related to CSCs, many of which are FDA-approved drugs or drugs developed for preclinical or clinical trials, such as mTOR and Tyrosine kinase pathways. [74] [75] [76] Some tantalizing reports indicated that CSCs could be selectively targeted within haematopoietic malignancies, for researchers identified a naturally occurring molecule parthenolide as an agent selectively targeting human leukaemia stem cells only. 77 In a mouse model, Hoey et al. developed the anti-delta like 4 ligand (DLL4) agent, a component of Notch pathway, to reduce cancer cell proliferation by suppressing CSCs function with/without irinotecan. 78 In glioblastomas, bone morphogenetic proteins were testified to induce differentiation of CD133 þ CSC cells, which obviously suppressed tumor initiation potential. 79 
Treatment against CD133
þ CSCs with bevacizumab (Avastin) significantly inhibited their abilities to initiate tumors in vivo by suppressing angiogenesis with marginal efficacy against CD133 À cells in xenografted tumors, warranting a utility anti-CSCs drug. 80 CHK1/2 inhibitors, which could inhibit DNA damage checkpoint, may reduce CSCs radioresistance, particularly in combination with cytotoxic drugs. 47 Through interacting with pyruvate kinase M2, CD44 could enhance the glycolytic phenotype of cancer cells losing p53 or exposing to hypoxia, and methods inhibiting CD44 expression could decrease drug-resistance of CD44 þ cancer cells by promoting metabolic flux to mitochondrial respiration, suppressing entry into glycolysis and the pentose phosphate pathway. 81, 82 These resulted in exhaustion of cellular-reduced glutathione and accumulation of intracellular level of reactive oxygen species and concomitantly enhanced the effects of anticancer drugs in p53-deficient or hypoxic cancer cells. Ginestier et al. 83 used CXCR1 antibody or inhibitor to block IL-8 signaling to target and reduce breast CSCs population successfully in xenografts. Our in vivo experiments confirmed that overexpressed Dachshund reduced tumor formation by decreasing CSCs. 84 Therapeutic agents mentioned above seem to be specific and limited methods, for the strategies against CSCs should have a wide range of application with reliable effects.
THERAPEUTIC IMPLICATIONS OF MIRNAS IN REGULATING CSCS Aberrant miRNAs expression in CSCs
Followed by description of miRNAs and CSCs separately, miRNAs alternations in various CSCs will now be briefly summarized for developing therapies. Based on hundreds of expression-profiling researches, tumors ubiquitously exhibited dysregulated miRNA expression patterns relative to corresponding normal tissue. 10 CSCs are generally enriched for oncogenic genes and miRNAs, showing rare tumor-suppressive miRNAs. The expression levels of miRNAs were different between normal tissues and cancer, and the difference was much bigger between CSCs and normal tissues. 85, 86 Oncogenic miRNAs, such as LIN-28B, miR-9, miR-181 and miR-215 are responsible for tumor initiation or therapy resistance caused by CSCs, while let-7, miR-16, miR-34a/b, miR-122, miR-152 and miR-218 act as tumor suppressors lost in cancer and CSCs. Let-7, miR-16, miR-20b, miR-107 and three clusters of miR-200 were found much lower in Breast CSCs than in breast cancer cells, as well as in normal mammary cells. 51, 87 MiR-34a, let7b, miR-106a and miR-141 were downregulated in CD44 þ , CD133 þ , integrin a2b1 þ prostate CSCs and SP cells, whereas miR-301 and miR-452 increased. 88 In Breast CSCs, lung CSCs and prostate CSCs, let-7 and miR-200 could regulate cell properties of proliferation, cell cycle and metastasis through different targets and pathways as mentioned above. MiR-205 showed heterogeneity in ALDH1 þ mouse mammary progenitor cells and breast CSCs, and even varying in different stages of tumor development through influencing or being influenced by targeted genes. 89 MiR-34 was identified as a crucial regulator of glioblastoma CSCs and prostate CSCs by causing cell cycle arrest, apoptosis or xenograft tumor repression, which could be regulated by p53. 90 MiR-128, miR-199 and miR-451 also function in glioblastoma CSCs in their own way. 91 These miRNAs are known to be involved in CSCs regulation and associated chemoradiotherapy-resistant phenotype in different tumors and through targeting diverse genes; therefore, targeting specific miRNAs could be useful for killing CSCs preferentially, restoring therapy sensitivity and preventing tumor recurrence.
Regulation of CSCs by miRNAs
The roles of miRNAs interacting with stem cells were firstly noticed with the discovery of let-7 and lin-4, which were implicated in Caenorhabditis elegans (C. elegans) development and, since then, abundant miRNAs have emerged as important regulators. miRNAs played crucial roles in establishing and ensuring CSCs identity by maintaining core networks of TFs and RNA-binding proteins 41 ( Figure 4b) . Serving as the earliest-found and best-understood one, let-7 miRNAs family was testified to inhibit the malignancy of CSCs by targeting and repressing stemness factors and target genes, such as HMGA2, c-Myc, RAS, mitogen activated protein kinase, Notch. miRNAs were proved to be involved in tumor development of multiple processes by critically regulating CSCs and were also proved to be crucial regulators in CSCs self-renewal and differentiation by influencing implicated signal pathways and protein-coding genes. 91 MiR-200 regulates CSCs pools where CSCs sustain themselves, and in pancreatic and colorectal cancer, miR-200 repression induced by zinc finger E-box-binding homeobox protein could promote Sox2related CSCs proliferation. 43 MiR-200 could also modulate CSCs renewal by targeting B cell-specific MLV integration site-1 (BMI-1), and miR-34a directly suppress CD44 to restrict CSCs properties in breast CSCs, and as a transcriptional target of p53, mir-34 could also function in glioblastoma multiform, prostate, pancreatic and gastric CSCs repression 91 ( Figure 5 ). As we discussed in chapter 2.3, miRNAs affect diverse functions in the regulation of EMT and metastasis and could also be regulated by different signaling pathways related to EMT and metastasis, adding another layer to the intricate gene expression program underlying EMT. 19 Our unpublished data showed that Wnt and Notch pathways in CSCs self-regulation could be influenced by a bulk of miRNAs, most of which were regulated by Cyclin D1a or Cyclin D1b; and the regulation of p53 toward Cyclin-D1 and miRNAs seem to be implicated in cell cycle phase and stem cells asymmetric division ( Figure 5 ).
These results suggest that miRNAs play important roles in CSCs proliferation, differentiation and tumor formation, and exploration of miRNA expression profiles in various CSCs will be crucial for elucidating characters of CSCs, and then benefit to develop drugs or novel therapeutic methods to target and eliminate CSCs. Acting as novel and pivotal regulators of protein-encoding genes, miRNAs will have great potential in regulating CSCs' biological functions by targeting CSCs-related signal pathway molecules. However, this interaction of miRNAs targeting CSCs-related genes may be complicated, for regulatory loops among miRNAs and mRNAs did exist. Let-7 was implicated in IL-6/NF-kB/LIN-28/ let-7/ IL-6 loop, c-Myc /LIN-28B/let-7 circuit and LIN-28/let-7 axis 92 ( Figure 5 ). Our group recently identified that Cyclin-D1 was required for self-renewal and differentiation of stem cells and CSCs by regulating or being regulated by non-coding genome, and the miRNAs biogenesis in CSCs alternations could be feedback, 93 showed in Figure 5 .
miRNAs: acting as promising agents or targeting genes to kill CSCs The implications of miRNAs in tumor substantially advanced our knowledge about their roles in cancer biology, suggesting the tumor origin, clinical classification, tumor recurrence and prognosis in clinical practice. It is clear that each miRNA could influence many genes, implying comprehensive regulations may be achieved by antagonizing or inducing a single miRNA. 94 Exploration and understanding of the functions of miRNAs provides us new insights into cancer diagnoses and prognosis evaluation. A better and more complete understanding of miRNAs will undoubtedly yield diagnostic and therapeutic advances for anticancer treatment. Irregularly expressed miRNAs in CSCs were correlated with CSCs characteristics via multiple molecular mechanisms, while the critical questions are how could miRNAs be used and how do they work in a real battlefield?
Cancer-specific miRNA expression signature is very informative for diagnostic, therapeutic and prognostic purposes. Let-7 deregulation has been identified as a diagnostic and prognostic feature in clinical studies, as let-7a and let-7g were correlated with lung cancer survival. 95 Mallick et al. 96 reviewed biology and applications of miRNAs in lung cancer diagnosis and prognosis and confirmed that let-7 was a promising indicator. In breast cancer, let-7a and let-7f are related with lymph node metastasis and let-7c and let-7d are related with high proliferation index. 8, 97 For therapeutic roles, let-7 may be a powerful alliance to eradicate cancer. Kumar et al. 98 showed that let-7 functionally inhibits nonsmall cell tumor development, and Liu et al. 88 found that overexpression of let-7 inhibited prostate cancer cell proliferation, clonal expansion in vitro and tumor regeneration in vivo. Boyerinas et al. 99 testified that transfection of let-7i into A549 lung cancer cells sensitized these cells to one of ten novel chemotherapeutic compounds. All these proved that let-7 family members could be candidates for cancer diagnosis and prognosis and act as suitable agents for anticancer therapy. À phenotype made these cells sensitive to doxorubicin treatment compared with parental tumor cells. 100 In CD133 þ CSCs of glioblastoma, increased miR-145 inhibited tumor formation by negatively regulating SOX2, OCT4 and transformed CD133
þ CSCs into CD133
À cells by promoting differentiating, which were also sensitive to temozolomide with reduced antiapoptotic ability. 101 Cheng et al. 102 testified miR-199a significantly increased the chemosensitivity of ovarian CICs with CD44 þ /CD117 þ surface markers to cisplatin, pacitaxel and adriamycin by decreasing CD44 and ABCG2 expression levels. They also found that miR-199a suppressed the growth of xenograft tumors formed by ovarian CSCs in vivo, with several stemness markers significantly reducing. MiR-34a suppressed CD44 þ prostate CSCs metastasis by inhibiting CD44, and lengthened survival time of tumor bearing mice, while antagonist of miR-34a promoted tumor development and metastasis. 91, 103 Dicer is the key modulator in biogenesis of miRNAs, and its specialized role made it become a potent regulator in stem cells and CSCs (Figure 3b) . Albert et al. decreased the number of circulating endothelial progenitor cells, resulting in angiogenesis suppression and impaired tumor growth by using genetic ablation of the Dicer enzyme. They also testified the repression of miR-10b and miR-196b, which were key regulators of HOX signaling and were responsive to vascular endothelial growth factor stimulation, and targeting miR-10b and miR-196b led to angiogenesis-mediated tumor growth defections in mice. 104, 105 Difficulty, uncertainty, efficiency and prospective miRNAs-based molecular therapies towards CSCs aim at decreasing self-renewal capabilities, reducing resistance to current treatment as well as tumor relapse. However, some issues must be faced and fixed before application. On the one hand, single miRNA alone may be not sufficient to completely block malignancy generation and development, for example, when let-7 and miR-30 were both transfected into breast cancer stem cells, a more significant suppression of mammosphere forming and self-renewal were observed. 106 Increased let-7 could inhibit prostate cancer cell proliferation and clonal expansion, and the inhibitory effects may be better when use let-7 and miR-34a together, with miR-34a inducing G1 phase arrest accompanied by cell senescence and let-7 inducing G2-M phase arrest without senescence. 88 Cooperation of miRNAs may suggest better therapeutic effects. On the other hand, before clinical application, miRNA profiling of tumor versus normal tissue, especially CSCs versus the cancer cells and healthy cells, functional analysis of numerous and dizzy miRNAs and the tentative use of miRNA-based therapeutic methods (miRNA mimics, adenovirus, lentivirus and anti-miR) in vivo experiment should be evaluated. 104 What's more, besides these concerns, delivery, the biggest roadblock to utility by using miRNAs mimics or antagonists, should be faced boldly.
The therapeutic trial of miRNA mimics or vectors in animals showed suppressed effects of tumor growth; however, the ideal delivery system should possess the ability for high transfection efficiency, low cellular toxicity, low miRNAs degradation and tissue specific. 44 There are now multiple clinical trials underway using cationic liposomes for gene or chemotherapeutics delivery, such as doxorubicin on the market for breast cancer chemotherapy, and it will be more specific when bearing ligands recognized by cell surface receptors. 104 Nanoparticle-DNA lipoplex system has been developed and has shown prospective efficiency and specificity in targeted delivery. Transferrin and transferrin receptor-scFv-targeted nanovectors are in the procedure of animal models or clinical testing. 104, 107 Nanoparticle-based let-7 replacement therapy had been successfully applied in vivo; and TUTase-mediated LIN28, which is a facile target inhibited by pharmacologic compounds, could relieve let-7 maturation repression. 108 Some other miRNAs were useful in human acute myeloid leukaemia subtype. 109 Systemic delivery of synthetic let-7b and miR-34a mimics in complex with neutral lipid emulsion significantly decreased tumor burden in mouse model of nonsmall cell lung cancer. 110 Chemically synthesized miR-34a and a lipid-based delivery vehicle also suppressed tumor growth in mice models of non-small cell lung cancer in another group. 111 Interestingly, oncogenic miRNAs and suppressive miRNAs were demonstrated to show different patterns in function, interactive strength, expression and targets, which may result in discriminative effects when up or downregulated in therapeutic treatments; therefore, which to be taken as a weapon is worth considering. 112 The link between miRNAs and CSCs, miRNAs in self-renewal and the prospective therapeutic potential against cancer progression, resistance and relapse has now put miRNAs-based treatments in center stage. However, we should notice that miRNAs were often implicated in multiple regulatory loops, influenced by intracellular or extracellular microenvironment, which made their identification unclear when in different situation. Regulating one miRNA may result in unpredictable results, as regulatory loops and feedback loops among let-7 and mRNAs we discussed above and the possible carcinogenesis of let-7 just represent the tip of the iceberg. 92 Our recent progress showed regulatory loops among let-7 miRNAs and targeted genes in CSCs and also noticed that cyclin-D1 could regulate CSCs fates by influencing a bulk of miRNAs, including let-7 and miRNA-17/20, which may have a direct feedback loop with cyclin-D1 or through epigenetic Dicer. Other ongoing research and Zhang et al. 113 revealed that Cyclin-D1 could upregulate let-7 to work as a bad gene Let-7 also frustrates us with its repressive function on tumor suppressive caspase-3 and BCL2-associated X protein gene. The more comprehensive understanding of miRNAs in every single regulation loop, signal pathway and subtype CSCs will undoubtedly make miRNAs-based treatments precise and secure, and yield therapeutic advances for anticancer treatment.
CONCLUSION
MiRNAs play crucial roles in carcinogenesis, tumor development and metastasis. CSCs are considered as the origin of cancer and contribute to the recurrence and metastasis; therefore, the mutual relationships between these two parts seem to be interesting and important. The promotion or inhibition of miRNAs to the initiation and progression of malignancies by influencing CSCs should be further exploited to achieve novel improvements in existing diagnostic and therapeutic approaches. To achieve this, miRNA signatures with their implicated signaling pathways of CSCs and cancer subtypes must be identified first. Since a single miRNA could regulate multiple downstream mRNAs, restoring the lost miRNAs or repressing the overloaded miRNAs in malignancies and CSCs showed potent effects on various signaling pathways to induce therapeutic results. Besides, it is more feasible to choose miRNAs involved in particular processes as targets even without knowing all of the genes involved. Then the derivatives of smallmolecule compounds, therapeutic agents and monoclonal antibodies designed to target implicated miRNAs in CSCs could be used in clinical treatment, and some systemic delivery methods have been created and tested. However, the labyrinth from basic research to clinical application is still long and winding. More clinical evidence is needed to support the application of miRNAs in treating cancer and CSCs; also, the validity and security of targeted therapies based on miRNAs should be carefully evaluated and boldly attempted. Molecular therapies may be most effective when used in combination with cytotoxic therapies or targeted therapies, meaning conventional therapies will remain the mainstays of anticancer treatment. It has to be kept in mind that cytokine, chemokine and growth factors of the extracellular matrix also play important roles in development of heterogeneous tumor population, which must be considered in miRNAs-based treatments to avoid the prepared plan from being disturbed.
